Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

Eli Lilly

25 February 2021 - The first and only anti-CGRP treatment with dual indications.

Eli Lilly Canada is pleased to announce that Emgality (galcanezumab) is now indicated for the reduction in the frequency of attacks throughout a cluster period in adults with episodic cluster headache with prior cluster headache periods lasting at least 6 weeks and who have had an inadequate response to, or tolerated poorly, or had contra-indications to conventional preventive therapies established by Canadian practice guidelines.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada